STOCK TITAN

Organogenesis Holdings Inc. Updates Date and Time of Presentation at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

CANTON, Mass., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that the date and time of its presentation at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit has been updated.

Company management is now scheduled to conduct a presentation at the conference on Monday, September 21 at 2:30 p.m. Eastern Time. The company was previously scheduled to present on Tuesday, September 22 at 4:10 p.m. Eastern Time.

A live audio webcast of the conference presentation will be accessible by visiting the “Upcoming Events” section on the “Investor Relations” page of Organogenesis’s website www.organogenesis.com. An archive of the webcast will be available for replay following the conference for approximately 30 days.

About Organogenesis Holdings Inc.
Organogenesis Holdings Inc. is a leading regenerative medicine company offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Organogenesis’s comprehensive portfolio is designed to treat a variety of patients with repair and regenerative needs. For more information, visit www.organogenesis.com.

Investor Inquiries:
Westwicke Partners
Mike Piccinino, CFA

443-213-0500

Press and Media Inquiries:
Organogenesis
Marcus Girolamo
 
817-688-4767

Organogenesis Holdings Inc.

NASDAQ:ORGO

ORGO Rankings

ORGO Latest News

ORGO Stock Data

363.25M
61.84M
33.32%
44.97%
5.48%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
CANTON

About ORGO

headquartered in canton, massachusetts, organogenesis inc. is a global leader in regenerative medicine, offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. organogenesis’ versatile portfolio is designed to treat a variety of patients with repair and regenerative needs.